` BIOR (Biora Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

BIOR
vs
S&P 500

Over the past 12 months, BIOR has underperformed S&P 500, delivering a return of -97% compared to the S&P 500's 12% growth.

Stocks Performance
BIOR vs S&P 500

Loading

Performance Gap
BIOR vs S&P 500

Loading
BIOR
S&P 500
Difference

Performance By Year
BIOR vs S&P 500

Loading
BIOR
S&P 500
Add Stock

Competitors Performance
Biora Therapeutics Inc vs Peers

Biora Therapeutics Inc
Glance View

Market Cap
994.4k USD
Industry
Health Care

Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.

BIOR Intrinsic Value
Not Available
Back to Top